Botulinum Toxin Injections for Oral Neuropathic Pain
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Peripheral painful traumatic trigeminal neuropathy (PPTTN) are poorly relieved by existing
treatments which in addition induce many adverse effects. BTX, which blocks the exocytosis of
neurotransmitters, can be captured by axonal retrograde transport in primary nociceptive
neurons. Injected in the painful area, it might therefore inhibit the release of algogenic
neurotransmitters, at both the peripheral and central levels and thus reduce pain. One study
reported such an effect in neuropathic spinal pain. A recent study reported an analgesic
effect in trigeminal neuralgia.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Karolinska Institutet University of Aarhus
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A onabotulinumtoxinA Pharmaceutical Solutions